2026-05-21T23:00:10Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/204912024-11-28T19:38:11Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Di Minno, Giovanni author Navarro, David author Perno, Carlo Federico author Canaro Hirnyk, Mariana author Guertler, Lutz author Ironside, James W author Eichler, Hermann author Tiede, Andreas author 2017-08 Patients with blood disorders (including leukaemia, platelet function disorders and coagulation factor deficiencies) or acute bleeding receive blood-derived products, such as red blood cells, platelet concentrates and plasma-derived products. Although the risk of pathogen contamination of blood products has fallen considerably over the past three decades, contamination is still a topic of concern. In order to counsel patients and obtain informed consent before transfusion, physicians are required to keep up to date with current knowledge on residual risk of pathogen transmission and methods of pathogen removal/inactivation. Here, we describe pathogens relevant to transfusion of blood products and discuss contemporary pathogen removal/inactivation procedures, as well as the potential risks associated with these products: the risk of contamination by infectious agents varies according to blood product/region, and there is a fine line between adequate inactivation and functional impairment of the product. The cost implications of implementing pathogen inactivation technology are also considered. Di Minno Giovanni, Navarro David, Perno Carlo Federico, Canaro Hirnyk Mariana, Guertler Lutz, Ironside James W., et al. Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?. Ann Hematol. 2017 Aug;96(8):1253-1270. Epub 2017 Jun 18. 10.1007/s00277-017-3028-4 1432-0584 0939-5555 Annals of Hematology http://hdl.handle.net/20.500.13003/9729 28624906 L616848849 2-s2.0-85020513631 http://hdl.handle.net/20.500.12105/20491 404207100002 Pathogen Inactivation Virus Removal Blood Clotting Bleeding disorder Infection risk Patient information Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?